Of note, PI3K/AKT/mTOR signaling has been described to be involved in resistance to specific inhibitors classically employed in NMSCs, due to the intricate crosstalk between different pathways in these skin cancers (70, 117). The gene discussed is MTOR; the disease is skin cancer.